TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Rating of "Buy" from Brokerages

Key Points

• TuHURA Biosciences, Inc. has received an average rating of "Buy" from five analysts, with a target price of $12.67.
• Institutional investors have significantly increased their holdings in TuHURA, with Geode Capital Management boosting its ownership by 111.4% in Q2.
• Despite a recent earnings report that missed estimates, TuHURA's stock has shown a 6.6% increase and currently trades at around $3.25.

TuHURA Biosciences, Inc. (NASDAQ:HURA - Get Free Report) has earned an average rating of "Buy" from the five analysts that are currently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $12.6667.

Several equities analysts have recently issued reports on HURA shares. Wall Street Zen raised TuHURA Biosciences from a "sell" rating to a "hold" rating in a report on Friday, July 18th. Brookline Capital Management raised TuHURA Biosciences to a "strong-buy" rating in a report on Monday, June 23rd. Finally, HC Wainwright reissued a "buy" rating and set a $12.00 price objective on shares of TuHURA Biosciences in a report on Friday, May 16th.

Hedge Funds Weigh In On TuHURA Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of HURA. Geode Capital Management LLC boosted its holdings in shares of TuHURA Biosciences by 111.4% in the second quarter. Geode Capital Management LLC now owns 582,992 shares of the company's stock worth $1,300,000 after acquiring an additional 307,260 shares during the period. Apollon Wealth Management LLC boosted its holdings in shares of TuHURA Biosciences by 86.0% in the first quarter. Apollon Wealth Management LLC now owns 114,926 shares of the company's stock worth $371,000 after acquiring an additional 53,154 shares during the period. Suncoast Equity Management boosted its holdings in shares of TuHURA Biosciences by 4.4% in the second quarter. Suncoast Equity Management now owns 104,409 shares of the company's stock worth $233,000 after acquiring an additional 4,412 shares during the period. Northern Trust Corp bought a new position in shares of TuHURA Biosciences in the fourth quarter worth $234,000. Finally, Squarepoint Ops LLC bought a new position in shares of TuHURA Biosciences in the fourth quarter worth $223,000. 0.62% of the stock is owned by institutional investors.

TuHURA Biosciences Stock Up 6.6%

HURA stock opened at $3.25 on Wednesday. The business has a 50 day moving average of $2.58 and a 200-day moving average of $3.23. TuHURA Biosciences has a 12-month low of $1.80 and a 12-month high of $8.63.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02).

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.